Headquartered in Arlington, VA·Fiscal year ends December·NYSE: EVH·evolent.com
About Evolent Health
Evolent Health provides specialty care management solutions to health plans (payers) and providers, aimed at improving outcomes and lowering costs for people with complex conditions such as cancer, cardiovascular disease and musculoskeletal disorders. It reports four revenue lines:
- **Performance Suite:** risk-based specialty care management, in which Evolent takes on medical cost risk for covered members and earns per-member-per-month fees. This line now makes up the large majority of revenue.
- **Specialty Technology and Services Suite:** administrative services only (ASO) arrangements covering oncology, cardiology, musculoskeletal, advanced imaging and other diagnostics.
- **Administrative Services:** health plan administration services.
- **Cases:** surgical management, from the IPG business acquired in 2022, and advanced care planning programs.
Oncology is a central growth area, including 2026 launches and expansions into additional states, alongside offerings such as Member Navigation. The company is also building an AI platform. Evolent sold its value-based provider business, Evolent Care Partners, in December 2025. The company serves a national base of payers and providers and carries significant debt, including convertible notes and first and second lien credit facilities. Updated
The medical expense ratio jumped to 93.0% from 85.0%, shrinking adjusted EBITDA to $34.3 million even as oncology launches nearly doubled Performance Suite revenue. Management still raised full-year adjusted EBITDA guidance to $130 million to $135 million. How fast that margin recovers is the whole story.
Healthcare payrolls keep climbing, and hospital systems, payers, and clinics are now openly treating agentic AI as the cheapest unit of labor on the market. Stocks trading under $20 with credible agentic…
Evolent Health provides specialty care management solutions to health plans (payers) and providers, aimed at improving outcomes and lowering costs for people with complex conditions such as cancer, cardiovascular disease and musculoskeletal disorders.
What is the EVH stock price target?
24/7 Wall St.'s 12-month price target for EVH is $6.34, rated Buy. The Wall Street consensus target is $6.00. EVH price prediction →